Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions

Oral Cavity Carcinoma Clinical Trial

Official title:

Metformin Chemoprevention of Oral Premalignant Lesions

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT05536037
• Other study ID #: 22D.296
• Status: Terminated
• Phase: Phase 1
• Start date: May 4, 2022
• Est. completion date: March 16, 2024

Study information

• Verified date: April 2024
• Source: Thomas Jefferson University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase I trial tests whether metformin works in reducing the annual transformation (development of invasive cancer) of oral precancerous lesions into cancerous lesions. Metformin is a drug approved for the treatment of diabetes, but studies have shown that it may have some anticancer properties. Giving metformin may help prevent or slow the development of oral cancer from precancerous lesions.

Description:

PRIMARY OBJECTIVE: I. To evaluate the transformation-free-survival in lesion types erythroplakia (EP) and verrucous hyperplasia (VH). 'Transformation' is defined as the development of invasive cancer. SECONDARY OBJECTIVE: I. To evaluate the current spontaneous regression rates, i.e., percentages of patients having lesion disappear within 1-year post treatment, in all four lesion types and compare them with historical documented regression rate in literature. EXPLORATORY OBJECTIVE: I. To evaluate the transformation-free-survival in lesion types homogenous leukoplakia (HL) and non-homogenous leukoplakia (NHL). OUTLINE: Patients receive metformin orally (PO) once daily (QD) on days 1-3 and then PO twice daily (BID) for up to 12 months in the absence of unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 24 months.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: March 16, 2024
• Est. primary completion date: March 16, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Age 18-85
• Clinical appearance of lesion
• Homogenous leukoplakia
• Non- homogenous leukoplakia
• Erythroplakia
• Proliferative verrucous leukoplakia
• Histologic appearance
• No dysplasia
• Mild dysplasia
• Moderate dysplasia
• Severe dysplasia
• Diabetics: if on metformin, will get them to 2000 mg per day, if not, will add metformin in consultation with endocrinologist
• All subjects must be able to comprehend and sign a written informed consent document
• Willing and able to be available for the duration of the study
• In general good health with no contraindication to biopsy or metformin therapy
• Laboratory results

Exclusion Criteria:

• Carcinoma in-situ, verrucous carcinoma, invasive squamous cell carcinoma (SCCa)
• Exclude systemic causes of the lesion: pemphigus, pemphigoid, systemic lupus erythematosus (SLE), lichenoid drug reaction, human immunodeficiency virus (HIV), syphilis
• Exclude local inciting factors: rule out (r/o) but allowing 2 weeks to pass and see if there is resolution, if not and doesn't resolve with local measures, medical treatment, enroll
• Frictional: sharp tooth
• Trauma
• Immunosuppression by natural illness or medically induced
• Hypersensitivity or allergic reaction to metformin or some other contraindication

Related Conditions & MeSH terms

• Erythroplakia
• Erythroplasia
• Leukoplakia
• Oral Cavity Carcinoma
• Precancerous Conditions
• Proliferative Verrucous Leukoplakia

Intervention

Drug:
• Metformin
Given PO

Procedure:
• Biopsy
Undergo biopsy

Locations

Country	Name	City	State
United States	Thomas Jefferson University Hospital	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Thomas Jefferson University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Transformation-free-survival, in lesion types homogenous leukoplakia and non-homogenous leukoplakia	Will be summarized using Kaplan-Meier curves as well as 95% confidence ands. Kaplan-Meier estimates of the 3-year transformation-free-survival rates will be reported with 95% confidence interval. One-sample two-sided log-rank test will be applied to all four lesions as well.	Up to 3 years
Primary	Transformation-free-survival, in lesion types erythroplakia and verrucous hyperplasia	Will be summarized using Kaplan-Meier curves as well as 95% confidence ands. Kaplan-Meier estimates of the 3-year transformation-free-survival rates will be reported with 95% confidence interval. One-sample two-sided log-rank test will be applied to all four lesions as well.	Up to 3 years
Secondary	Change in lesion status	Evaluated on a Likert-scale with three levels: 'worsen', 'same' and 'disappear', compared to each patient's baseline lesion status (as measured at pre-treatment and one year post initiation of treatment). The lesion size and status evaluated at 1-year post-treatment will be summarized using percentages as well as 95% Clopper-Pearson exact confidence intervals. The current spontaneous regression rates (i.e., percentage of 'disappear') will be compared against the historically documented regression rate of 35% using two-sided exact binomial test.	Baseline to 1 year after treatment